Virginia Retirement Systems ET AL lessened its stake in Clovis Oncology (NASDAQ:CLVS – Get Rating) by 46.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 16,500 shares of the biopharmaceutical company’s stock after selling 14,300 shares during the period. Virginia Retirement Systems ET AL’s holdings in Clovis Oncology were worth $45,000 as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of the company. Alliancebernstein L.P. increased its holdings in Clovis Oncology by 67.1% in the third quarter. Alliancebernstein L.P. now owns 365,800 shares of the biopharmaceutical company’s stock valued at $1,631,000 after buying an additional 146,900 shares during the last quarter. UBS Group AG lifted its holdings in Clovis Oncology by 213.9% during the 3rd quarter. UBS Group AG now owns 947,503 shares of the biopharmaceutical company’s stock worth $4,226,000 after buying an additional 645,662 shares during the last quarter. E Fund Management Co. Ltd. acquired a new position in shares of Clovis Oncology in the 3rd quarter worth approximately $176,000. Geode Capital Management LLC increased its holdings in shares of Clovis Oncology by 9.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,020,571 shares of the biopharmaceutical company’s stock valued at $9,011,000 after acquiring an additional 173,838 shares during the last quarter. Finally, Rafferty Asset Management LLC raised its position in shares of Clovis Oncology by 58.4% during the 3rd quarter. Rafferty Asset Management LLC now owns 714,688 shares of the biopharmaceutical company’s stock valued at $3,188,000 after acquiring an additional 263,392 shares in the last quarter. 48.81% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have recently issued reports on CLVS shares. StockNews.com assumed coverage on shares of Clovis Oncology in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Clovis Oncology in a report on Thursday, February 24th.
Clovis Oncology (NASDAQ:CLVS – Get Rating) last announced its earnings results on Wednesday, February 23rd. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.11. The company had revenue of $35.97 million for the quarter, compared to the consensus estimate of $39.30 million. During the same period in the previous year, the company earned ($0.74) EPS. On average, equities research analysts predict that Clovis Oncology will post -1.59 EPS for the current year.
Clovis Oncology Company Profile (Get Rating)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.